Literature DB >> 7990927

Drug excretion mediated by a new prototype of polyspecific transporter.

D Gründemann1, V Gorboulev, S Gambaryan, M Veyhl, H Koepsell.   

Abstract

Cationic drugs of different types and structures (antihistaminics, antiarrhythmics, sedatives, opiates, cytostatics and antibiotics, for example) are excreted in mammals by epithelial cells of the renal proximal tubules and by hepatocytes in the liver. In the proximal tubules, two functionally disparate transport systems are involved which are localized in the basolateral and luminal plasma membrane and are different from the previously identified neuronal monoamine transporters and ATP-dependent multidrug exporting proteins. Here we report the isolation of a complementary DNA from rat kidney that encodes a 556-amino-acid membrane protein, OCT1, which has the functional characteristics of organic cation uptake over the basolateral membrane of renal proximal tubules and of organic cation uptake into hepatocytes. OCT1 is not homologous to any other known protein and is found in kidney, liver and intestine. As OCT1 translocates hydrophobic and hydrophilic organic cations of different structures, it is considered to be a new prototype of polyspecific transporters that are important for drug elimination.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990927     DOI: 10.1038/372549a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  115 in total

1.  Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters.

Authors:  I Wessler; E Roth; C Deutsch; P Brockerhoff; F Bittinger; C J Kirkpatrick; H Kilbinger
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Hepatocellular transport proteins and their role in liver disease.

Authors:  C Stanca; D Jung; P J Meier; G A Kullak-Ublick
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

3.  Quantitative evaluation of capacity-limited hepatobiliary transport based on hepatocellular diffusion model by MULTI(FEM).

Authors:  M Higashimori; K Yamaoka; S Fujitani; T Nakagawa
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

Review 4.  Measurement of renal function during drug development.

Authors:  D Craig Brater
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

5.  Expression of the extraneuronal monoamine transporter (uptake2) in human glioma cells.

Authors:  S Streich; M Brüss; H Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

6.  Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.

Authors:  Jessica J Howell; Kristina Hellberg; Marc Turner; George Talbott; Matthew J Kolar; Debbie S Ross; Gerta Hoxhaj; Alan Saghatelian; Reuben J Shaw; Brendan D Manning
Journal:  Cell Metab       Date:  2017-01-12       Impact factor: 27.287

Review 7.  Regulation of organic cation transport.

Authors:  Giuliano Ciarimboli; Eberhard Schlatter
Journal:  Pflugers Arch       Date:  2004-11-16       Impact factor: 3.657

8.  Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.

Authors:  Jaclyn N Harper; Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-03

Review 9.  Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution.

Authors:  Thomas Gerloff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

10.  Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics.

Authors:  Britta Haenisch; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.